Introduction
Methods
Patients and samples
Real-time quantitative PCR
Mass spectrometry-based quantification of adrenal precursors, androgens, estrogens, and catechol estrogens
Statistical analysis
Results
Characteristics of CLL patients
Characteristics | Na | Men | Women |
---|---|---|---|
Number of patients | 156 | 95 | 61 |
Median age (years) | 138 |
59.8
|
62.9
|
Markers | |||
Binet stage B or Cb | 131 | 17.5% | 7.8% |
High CD38 expressionb | 146 | 31.8% | 20.0% |
Positive Coombs test | 150 | 2.2% | 1.7% |
Cytogenetic abnormalities | |||
17p deletion | 97 | 6.7% | 5.4% |
11q deletionb | 149 | 15.4% | 19.0% |
Trisomy 12b | 149 | 11.0% | 8.6% |
13q deletion | 149 | 58.2% | 51.7% |
14q aberrations | 149 | 14.3% | 12.1% |
Unmutated IGHVb | 134 | 50.1% | 40.4% |
IGHV gene usageb | |||
1–69 | 114 | 16.2% | 14.6% |
3–21 | 114 | 4.1% | 4.9% |
3–23 | 114 | 8.1% | 4.9% |
Treatment-free survival (TFS) | |||
Median (months)c | 156 |
80.7
|
135.0
|
Patients requiring treatment | 156 |
67.4% (64)
|
44.3% (27)
|
Overall survival (OS) | |||
30th percentile (months)c | 156 | 161.2 |
191.1
|
Levels of hormones in CLL patients differ by sex and from those of healthy donors
Treatment-free survival is associated with levels of circulating hormones
Plasma steroid levels | HRc (95% CI) (n = 95) | HRadjd (95% CI) (n = 84) | HRadje (95% CI) (n = 84) |
---|---|---|---|
Adrenal precursors | |||
DHEA-S (μg/ml) | 1.02 (0.80–1.31) | 0.87 (0.63–1.19) | 0.86 (0.63–1.19) |
DHEA (ng/ml) | 0.94 (0.67–1.31) | 0.86 (0.60–1.12) | 0.87 (0.61–1.23) |
5-Diol (pg/ml) | 0.93 (0.71–1.21) | 0.95 (0.72–1.25) | 0.96 (0.73–1.26) |
Androgens | |||
4-Dione (ng/ml) | 0.89 (0.55–1.44) | 1.01 (0.60–1.72) | 1.03 (0.61–1.75) |
Testo (ng/ml) | 1.14 (0.79–1.66) | 0.84 (0.53–1.33) | 0.85 (0.53–1.34) |
DHT (pg/ml) | 1.20 (0.88–1.64) | 0.96 (0.68–1.37) | 0.96 (0.67–1.35) |
ADT (pg/ml) | 1.09 (0.76–1.58) | 1.05 (0.66–1.67) | 1.04 (0.66–1.65) |
3β-Diol (pg/ml) | 0.92 (0.68–1.25) | 0.88 (0.60–1.29) | 0.88 (0.60–1.29) |
ADT-G (ng/ml) | 1.22 (0.88–1.70) |
1.01 (0.70–1.47)
|
1.02 (0.70–1.48)
|
3α-Diol-17G (ng/ml) | 1.14 (0.88–1.46) | 0.71 (0.50–1.02) | 0.72 (0.50–1.03) |
3α-Diol-3G (ng/ml) | 1.12 (0.77–1.61) | 0.87 (0.57–1.33) | 0.87 (0.57–1.32) |
Estrogens | |||
E1-S (ng/ml) | 1.06 (0.80–1.40) | 0.79 (0.58–1.08) | 0.78 (0.57–1.07) |
E1 (pg/ml) |
0.61 (0.35–1.08)
| 1.00 (0.51–1.99) | 1.01 (0.51–2.00) |
E2 (pg/ml) | 0.86 (0.60–1.22) | 0.77 (0.52–1.14) | 0.76 (0.51–1.13) |
Receptor ligandsa | |||
ER-ligands (pg/ml) | 0.92 (0.66–1.29) | 0.93 (0.67–1.30) | 0.94 (0.67–1.31) |
AR-ligands (ng/ml) | 1.14 (0.78–1.67) | 0.84 (0.53–1.33) | 0.84 (0.53–1.34) |
Catechol estrogens (CE)b | |||
2/4OH-CE (pg/ml) |
0.77 (0.57–1.04)
| 0.80 (0.54–1.20) | 0.78 (0.52–1.17) |
16OH-CE (pg/ml) |
1.33 (0.95–1.85)
| 1.32 (0.86–2.02) | 1.32 (0.86–2.02) |
MeO-CE (pg/ml) |
1.56 (0.92–2.65)
| 1.27 (0.70–2.32) | 1.28 (0.65–2.49) |
Pituitary gonadotropins | |||
LH (mIU/ml) |
1.35 (0.97–1.89)
|
2.11 (1.27–3.53)
|
2.11 (1.26–3.53)
|
FSH (mIU/ml) |
1.42 (1.04–1.94)
| 1.43 (0.91–2.23) | 1.42 (0.91–2.23) |
Plasma steroid levels | HRc (95% CI) (n = 61) | HRadjd (95% CI) (n = 44) | HRadje (95% CI) (n = 44) |
---|---|---|---|
Adrenal precursors | |||
DHEA-S (μg/ml) | 0.81 (0.54–1.20) | 0.95 (0.51–1.78) | 0.95 (0.49–1.82) |
DHEA (ng/ml) |
0.63 (0.41–0.97)
| 0.68 (0.33–1.41) | 0.62 (0.27–1.42) |
5-Diol (pg/ml) | 0.95 (0.69–1.30) |
0.64 (0.41–1.01)
|
0.64 (0.40–1.01)
|
Androgens | |||
4-Dione (ng/ml) |
0.31 (0.15–0.65)
|
0.34 (0.10–1.16)
|
0.25 (0.06–1.02)
|
Testo (ng/ml) |
0.35 (0.20–0.77)
|
0.24 (0.08–0.67)
|
0.24 (0.08–0.67)
|
DHT (pg/ml) |
0.47 (0.31–0.72)
|
0.54 (0.32–0.92)
|
0.53 (0.31–0.91)
|
ADT (pg/ml) |
0.70 (0.48–1.01)
| 0.79 (0.44–1.43) | 0.76 (0.40–1.46) |
3β-Diol (pg/ml) | 0.70 (0.43–1.14) | 0.75 (0.31–1.79) | 0.74 (0.31–1.80) |
ADT-G (ng/ml) |
0.51 (0.31–0.83)
| 0.83 (0.40–1.71) | 0.81 (0.37–1.75) |
3α-Diol-17G (ng/ml) | 0.65 (0.38–1.11) | 1.09 (0.56–2.12) | 1.09 (0.56–2.13) |
3α-Diol-3G (ng/ml) | 0.73 (0.46–1.18) | 0.90 (0.49–1.67) | 0.89 (0.47–1.71) |
Estrogens | |||
E1-S (ng/ml) | 0.82 (0.51–1.33) | 1.11 (0.57–2.16) | 1.12 (0.57–2.17) |
E1 (pg/ml) | 0.63 (0.37–1.05) | 1.16 (0.53–2.57) | 1.17 (0.52–2.62) |
E2 (pg/ml) | 0.84 (0.65–1.01) | 0.61 (0.30–1.23) | 0.60 (0.30–1.23) |
Receptor ligandsa | |||
ER-ligands (pg/ml) | 0.92 (0.62–1.35) |
0.59 (0.34–1.03)
|
0.59 (0.33–1.04)
|
AR-ligands (ng/ml) |
0.37 (0.19–0.73)
|
0.27 (0.10–0.70)
|
0.26 (0.10–0.70)
|
Catechol estrogens (CE)b | |||
2/4-OH-CE (pg/ml) | 0.80 (0.49–1.28) | 0.81 (0.46–1.44) | 0.68 (0.33–1.41) |
16OH-CE (pg/ml) | 0.97 (0.65–1.43) | 0.86 (0.38–1.94) | 0.87 (0.39–1.95) |
MeO-CE (pg/ml) |
0.52 (0.26–1.04)
|
0.31 (0.11–0.92)
|
0.19 (0.05–0.69)
|
Pituitary gonadotropins | |||
LH (mIU/ml) | 0.81 (0.46–1.42) | 1.34 (0.43–4.18) | 1.35 (0.44–4.18) |
FSH (mIU/ml) | 1.18 (0.45–3.07) | 1.10 (0.25–4.89) | 1.10 (0.25–4.88) |
UGT2B17 mRNA expression in peripheral mononuclear blood cells is associated with TFS
Men (n = 81) | Women (n = 51)e | |||||
---|---|---|---|---|---|---|
Characteristics | Na | UGT2B17-high | UGT2B17-low |
N
a
| UGT2B17-high | UGT2B17-low |
% (39) | % (42) | % (27) | % (24) | |||
Markersb | ||||||
Binet stage B or C | 66 | 16.1% | 17.1% | 42 | 13.0% | 5.3% |
High CD38 expression | 77 | 39.5% | 25.6% | 46 |
37.5%
| 4.5% |
Positive Coombs test | 79 | 2.6% | 2.4% | 48 | 0.0% | 4.5% |
Cytogenetic abnormalitiesb | ||||||
17p deletion | 49 | 5.0% | 6.9% | 30 | 12.5% | 0.0% |
11q deletion | 77 | 22.9% | 9.5% | 49 |
29.6%
| 4.5% |
Trisomy 12 | 77 | 11.4% | 11.9% | 49 | 11.1% | 45.5% |
13q deletion | 77 | 48.6% | 69.0% | 49 | 51.9% | 4.5% |
14q aberrations | 77 | 11.4% | 19.0% | 49 | 11.1% | 18.2% |
Unmutated IGHV | 74 |
69.4%
| 28.9% | 41 |
66.7%
| 11.8% |
IGHV gene usage | ||||||
1–69 | 61 | 23.3% | 9.7% | 36 | 22.7% | 7.1% |
3–21 | 61 | 0.0% | 6.5% | 36 | 9.1% | 0.0% |
3–23 | 61 | 3.3% | 16.1% | 36 | 4.5% | 7.1% |
Survival analysisb | ||||||
TFS, median (month)c |
80.7
|
87.8
|
74.1
|
126.3
| ||
Requiring treatment | 76.9% | 57.1% | 59.3% | 36.4% | ||
Survival analysis (all cases)d | ||||||
TFS, median (month)c | 80.7 | 87.2 |
74.1
|
225.9
| ||
Requiring treatment | 76.9% | 60.7% |
59.3%
|
50.0%
|